There are cracks forming in the façade of the stock market right now. The best and brightest stocks of the last few months ...

Eli Lilly's bet on the Oscars shows the GLP-1 ad wars are heating up. - Eli Lilly. At the 2024 Academy Awards, Eli Lilly, the ...

Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly launched an ad campaign on Friday, cautioning patients against the risks of unapproved weight-loss drugs in its ...

When asked whether we’ll ever find out who was behind the selloff, the CNBC TV show host stated: “Well no, and you never will ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Hims & Hers Health (NYSE:HIMS – Free Report) had its price objective hoisted by Leerink Partners from $24.00 to $40.00 in a report published on Tuesday,Benzinga reports. They currently have a market ...

Eli Lilly and Company, Hims & Hers Health, UnitedHealth Group, Walmart, Tempus AI, Johnson & Johnson, and Merck & Co., Inc. are the seven Medical stocks to watch today, according to MarketBeat’s stock ...

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...